ArticleInnovation (Cambridge (Mass.))2026
Plasma p-Tau217 improves diagnostic accuracy and clinician confidence in cognitive disorder classification.
Article in Innovation (Cambridge (Mass.)), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical utility of plasma phosphorylated tau at threonine 217 (p-tau217) levels as a diagnostic tool for cognitive disorders in real-world settings remains uncertain. In this cross-sectional retrospective study, 738 consecutive subjects presenting with cognitive complaints at a memory clinic underwent diagnostic evaluation incorporating plasma p-tau217 alongside standard clinical assessments ("tier 2": routine neuroimaging and cognitive testing) and advanced biomarker testing ("tier 1": amyloid positron emission tomography [PET] imaging or cerebrospinal fluid [CSF] analysis). Diagnostic impact and confidence were assessed using clinician surveys. Incorporating plasma p-tau217 into the routine tier 2 diagnostic workup significantly influenced clinical decision-making, leading to diagnostic revisions in 30.2% of cases and improving overall diagnostic confidence from 65.1% to 79.4%. Plasma p-tau217 demonstrated high diagnostic accuracy for Alzheimer's disease (AD), with a sensitivity of 0.88 and a specificity of 0.84. Notably, its specificity was superior to tier 2 diagnoses, whereas its sensitivity did not differ significantly. Plasma p-tau217 also exhibited non-inferior performance to tier 1 approaches in the diagnostic distribution of AD, though with marginally lower diagnostic confidence. For non-AD diagnoses, plasma p-tau217 significantly impacted the classification of synucleinopathies and performed comparably to tier 1 methods. In conclusion, plasma p-tau217 meaningfully impacted diagnostic precision and confidence in subjects presenting to a real-world memory clinic, offering a minimally invasive, cost-effective, and accessible alternative to state-of-the-art examinations. As the global population ages and cognitive disorders become more prevalent, the integration of plasma p-tau217 into routine practice has the potential to streamline diagnostic workflows and enhance the efficient utilization of medical resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.